517 related articles for article (PubMed ID: 12473065)
1. Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations.
Qin JZ; Bacon PE; Chaturvedi V; Bonish B; Nickoloff BJ
Exp Dermatol; 2002 Dec; 11(6):573-83. PubMed ID: 12473065
[TBL] [Abstract][Full Text] [Related]
2. Role of NF-kappaB activity in apoptotic response of keratinocytes mediated by interferon-gamma, tumor necrosis factor-alpha, and tumor-necrosis-factor-related apoptosis-inducing ligand.
Qin JZ; Bacon P; Chaturvedi V; Nickoloff BJ
J Invest Dermatol; 2001 Oct; 117(4):898-907. PubMed ID: 11676830
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
4. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
Ravi R; Bedi A
Cancer Res; 2002 Mar; 62(6):1583-7. PubMed ID: 11912124
[TBL] [Abstract][Full Text] [Related]
5. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Hermisson M; Weller M
Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
[TBL] [Abstract][Full Text] [Related]
6. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.
Varfolomeev E; Maecker H; Sharp D; Lawrence D; Renz M; Vucic D; Ashkenazi A
J Biol Chem; 2005 Dec; 280(49):40599-608. PubMed ID: 16227629
[TBL] [Abstract][Full Text] [Related]
7. Regulation of TNF-related apoptosis-inducing ligand-mediated death-signal pathway in human beta cells by Fas-associated death domain and nuclear factor kappaB.
Ou D; Wang X; Metzger DL; Robbins M; Huang J; Jobin C; Chantler JK; James RF; Pozzilli P; Tingle AJ
Hum Immunol; 2005 Jul; 66(7):799-809. PubMed ID: 16112027
[TBL] [Abstract][Full Text] [Related]
8. Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines.
Siervo-Sassi RR; Marrangoni AM; Feng X; Naoumova N; Winans M; Edwards RP; Lokshin A
Cancer Lett; 2003 Feb; 190(1):61-72. PubMed ID: 12536078
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling.
Harper N; Hughes MA; Farrow SN; Cohen GM; MacFarlane M
J Biol Chem; 2003 Nov; 278(45):44338-47. PubMed ID: 12920112
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein.
Frese S; Brunner T; Gugger M; Uduehi A; Schmid RA
J Thorac Cardiovasc Surg; 2002 Jan; 123(1):168-74. PubMed ID: 11782771
[TBL] [Abstract][Full Text] [Related]
11. Low-dose UV-radiation sensitizes keratinocytes to TRAIL-induced apoptosis.
Qin JZ; Bacon P; Panella J; Sitailo LA; Denning MF; Nickoloff BJ
J Cell Physiol; 2004 Jul; 200(1):155-66. PubMed ID: 15137068
[TBL] [Abstract][Full Text] [Related]
12. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells.
Knight MJ; Riffkin CD; Muscat AM; Ashley DM; Hawkins CJ
Oncogene; 2001 Sep; 20(41):5789-98. PubMed ID: 11593384
[TBL] [Abstract][Full Text] [Related]
13. Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.
Mitsiades N; Mitsiades CS; Poulaki V; Anderson KC; Treon SP
Expert Opin Investig Drugs; 2001 Aug; 10(8):1521-30. PubMed ID: 11772267
[TBL] [Abstract][Full Text] [Related]
14. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
15. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
He Q; Luo X; Huang Y; Sheikh MS
Oncogene; 2002 Sep; 21(39):6032-40. PubMed ID: 12203115
[TBL] [Abstract][Full Text] [Related]
16. Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex.
Izeradjene K; Douglas L; Delaney AB; Houghton JA
Cancer Res; 2004 Nov; 64(21):8036-44. PubMed ID: 15520213
[TBL] [Abstract][Full Text] [Related]
17. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
Poulaki V; Mitsiades CS; Kotoula V; Tseleni-Balafouta S; Ashkenazi A; Koutras DA; Mitsiades N
Am J Pathol; 2002 Aug; 161(2):643-54. PubMed ID: 12163389
[TBL] [Abstract][Full Text] [Related]
19. Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL.
Chawla-Sarkar M; Bauer JA; Lupica JA; Morrison BH; Tang Z; Oates RK; Almasan A; DiDonato JA; Borden EC; Lindner DJ
J Biol Chem; 2003 Oct; 278(41):39461-9. PubMed ID: 12881518
[TBL] [Abstract][Full Text] [Related]
20. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]